查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085500

乾眼症市場：依產品類型、治療方法、最終用戶和通路分類－2026-2032年全球市場預測

Dry Eye Syndrome Market by Product Type, Treatment Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乾眼症市場規模將達到 83.5 億美元，複合年成長率為 7.52%。

主要市場統計數據
基準年 2025 50.2億美元
預計年份：2026年 53.7億美元
預測年份 2032 83.5億美元
複合年成長率 (%) 7.52%

根據TFOS DEWS II的定義，乾眼症（也稱為乾眼症）是一種慢性、多因素引起的眼表疾病，其特徵是淚膜不穩定、發炎、高滲透壓狀態和神經感覺異常。這種疾病會影響視覺舒適度、閱讀速度、螢幕耐受性、隱形眼鏡配戴、術後恢復、職場效率和整體生活品質。

由於人口老化、電子設備使用時間延長、白內障和屈光矯正手術增多、自體免疫疾病、糖尿病、隱形眼鏡普及、空氣污染以及低濕度環境等因素，乾眼症市場規模正在擴大，所有這些因素都加重了蒸髮型和脫水型乾眼症的負擔。在診斷方法正從基於症狀的治療轉向客觀檢測、針對性處方治療、脂質層支持以及基於器械的瞼板腺功能障礙管理的地區，這種成長尤為顯著。

乾眼症現狀的變革性變化

乾眼症的治療正從使用人工淚液轉向基於作用機制的治療方案。臨床醫生擴大使用淚液滲透壓、發炎標記、眼表染色、淚液破裂時間、瞼板腺成像以及患者自述結局（PRO）工具來區分脫水性乾眼和蒸發眼，特別是瞼板腺功能障礙。

人工智慧（AI）的累積影響

人工智慧 (AI) 正逐漸成為乾眼症篩檢、診斷、臨床工作流程和病患監測等各個領域的累積驅動力。 AI 影像分析有助於量化瞼板腺功能障礙、眼瞼邊緣變化、眨眼模式、眼睛發紅和淚膜行為。同時，透過分析電子健康記錄，可以根據年齡、用藥情況、自體免疫疾病、糖尿病、眼科手術史以及長時間使用電子螢幕的職業等因素來識別高風險患者。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區是大規模成長市場，其成長動力主要來自人口老化、都市化進程加速、電子設備使用率高、隱形眼鏡配戴率高、污染風險增加，以及東協市場（包括中國、日本、印度、韓國、澳洲等國家）眼科醫療服務覆蓋範圍的擴大。北美地區憑藉其專業的眼科醫療網路、以驗光師主導的診斷​​、處方治療的普及、完善的監管管道以及患者對慢性眼表疾病的高度認知，仍然是一個重要的價值市場。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，都市區眼科醫療基礎設施的完善、醫療旅遊的興起、隱形眼鏡使用量的增加以及數位化生活方式的普及，推動了對診斷、潤滑劑、診斷藥物和臨床治療的需求成長，從而增強了市場發展勢頭。在海灣合作理事會國家，炎熱乾燥的氣候、室內空調的普及、長時間的螢幕使用以及對高品質醫療保健的投入，為先進診斷技術和處方藥的引進創造了有利環境，也因此產生了對乾眼症治療的強勁需求。

來自主要乾眼症市場關鍵國家的洞察

美國在處方藥創新、臨床試驗、醫療設備推廣和乾眼症治療的消費者認知方面處於主導地位。同時，加拿大憑藉著驗光師主導的照護和無防腐劑產品的普及，需求穩定成長。墨西哥和巴西是拉丁美洲的重要市場，這得益於私人眼科診所、零售藥局管道、都市化以及慢性病盛行率的上升。在歐洲，英國、德國、法國、義大利和西班牙都受益於完善的眼科醫療保健體系、人口老化和結構化的臨床路徑。然而，在俄羅斯，需求受制於當地的藥品供應、價格、監管要求和供應狀況。

為行業領導者提供的實用建議

產業領導者應優先考慮針對蒸發和脫水性乾眼症的差異化產品組合，包括不含防腐劑的配方、抗發炎藥物、脂質層產品系列以及用於治療瞼板腺功能障礙的醫療設備療法。證據生成應包括真實世界結果、患者報告的改善情況、客觀觀察的變化、長期安全性以及與標準療法的比較價值。

調查方法

本執行摘要基於經驗證的二手研究和檢驗資訊的整合，包括TFOS DEWS II的臨床定義、同行評審的乾眼流行病學研究、法律規範、產品核可、治療指南、醫療基礎設施指標以及區域可及性狀況。所有研究結果均經過交叉核對，以避免未經證實的結論，並反映當前的臨床和商業性實際情況。

結論

乾眼症正從一種常被忽視的不適症狀演變為一種需要臨床治療的慢性眼表疾病，這使得人們對有針對性、可衡量且長期有效的解決方案的需求日益成長。推動這一成長的因素包括人口老化、數位化、環境壓力、眼科手術、慢性發炎性疾病以及診斷工具的改進。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 乾眼症市場：依產品類型分類

  • 醫療設備
  • 眼藥水
  • 眼膠
  • 眼膏
  • 淚管栓塞

第8章：乾眼症市場：依治療類型分類

  • 人工淚液
  • 醫療器材
  • 營養保健品
  • 使用處方藥進行治療
    • 皮質類固醇
    • Cyclosporine
    • 重新定義 Grast

第9章：乾眼症市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第10章：乾眼症市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 乾眼症市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 乾眼症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 乾眼症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc.
  • AFT Pharmaceuticals Ltd.
  • Akorn Operating Company LLC
  • Alcon Inc.
  • Bausch+Lomb Corporation
  • Johnson & Johnson Services, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mitotech SA
  • Novaliq GmbH
  • Novartis AG
  • OASIS Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Rohto Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Similasan Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Thea Pharmaceuticals Ltd.
  • United Laboratories Co., Ltd.
  • Ursapharm Arzneimittel GmbH
  • Zhejiang Jianfeng Group Co., Ltd.
Product Code: MRR-4348D129FA98

The Dry Eye Syndrome Market is projected to grow by USD 8.35 billion at a CAGR of 7.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.02 billion
Estimated Year [2026] USD 5.37 billion
Forecast Year [2032] USD 8.35 billion
CAGR (%) 7.52%

Dry Eye Syndrome, also known as dry eye disease, is a chronic, multifactorial ocular surface disorder associated with tear film instability, inflammation, hyperosmolarity, and neurosensory abnormalities, as defined by TFOS DEWS II. The condition affects visual comfort, reading speed, screen tolerance, contact lens wear, post-surgical recovery, workplace productivity, and overall quality of life.

The dry eye syndrome landscape is expanding as aging populations, prolonged digital device use, cataract and refractive surgery volumes, autoimmune diseases, diabetes, contact lens adoption, air pollution, and low-humidity environments increase the burden of evaporative dry eye and aqueous-deficient dry eye. Growth is strongest where diagnosis is shifting from symptom-based care toward objective testing, targeted prescription therapies, lipid-layer support, and device-based management of meibomian gland dysfunction.

Transformative Shifts in the Dry Eye Landscape

The dry eye landscape is moving beyond artificial tears toward mechanism-based treatment pathways. Clinicians increasingly differentiate aqueous-deficient dry eye from evaporative dry eye, particularly meibomian gland dysfunction, using tear osmolarity, inflammatory markers, ocular surface staining, tear breakup time, meibography, and patient-reported outcome tools.

Commercial innovation is concentrated in preservative-free lubricants, anti-inflammatory therapies such as cyclosporine and lifitegrast, neurostimulation approaches, tear conservation, thermal pulsation, intense pulsed light, and lipid-targeted treatments. This shift is raising the value of evidence-backed products that demonstrate durable symptom relief, objective sign improvement, safety in chronic use, and compatibility with digital health-enabled eye care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across dry eye screening, diagnosis, clinical workflow, and patient monitoring. AI-supported image analysis can help quantify meibomian gland dropout, lid margin changes, blink patterns, ocular redness, and tear film behavior, while electronic health record analytics can identify high-risk patients based on age, medication exposure, autoimmune disease, diabetes, ocular surgery history, and screen-intensive occupations.

For manufacturers and providers, AI can improve trial design, segment patients by phenotype, support adherence programs, and personalize treatment escalation. Adoption will depend on clinically validated algorithms, transparent performance metrics, bias testing across diverse populations, cybersecurity controls, and alignment with medical device and software-as-a-medical-device regulations.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific represents a high-volume growth arena due to large aging populations, urbanization, high digital device exposure, contact lens use, pollution exposure, and rising access to ophthalmology services in China, Japan, India, South Korea, Australia, and ASEAN markets. North America remains a leading value market, supported by specialist eye care networks, optometry-led diagnosis, prescription therapy adoption, established regulatory pathways, and high patient awareness of chronic ocular surface disease.

Europe benefits from structured clinical practice, strong optometry and ophthalmology access, and regulatory emphasis on product safety, although pricing and reimbursement vary across countries. Latin America is expanding through private eye care, retail pharmacy access, and improving awareness in Brazil and Mexico. The Middle East faces elevated dry eye risk from arid climates, air conditioning, dust exposure, and screen use, while Africa remains underdiagnosed, with growth tied to access, affordability, professional training, and distribution expansion.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are gaining momentum as urban eye care infrastructure, medical tourism, rising contact lens use, and digital lifestyles increase diagnosis and demand for lubricants, diagnostics, and office-based procedures. GCC countries show strong need for dry eye management because hot, dry climates, indoor air conditioning, high screen exposure, and premium healthcare investment create a favorable environment for advanced diagnostics and prescription products.

The European Union provides a harmonized regulatory foundation for medical products, although market access and reimbursement decisions remain country-specific. BRICS countries offer scale, local manufacturing opportunities, and expanding middle-class demand, while the G7 continues to lead in clinical research, premium therapeutics, diagnostic adoption, and evidence-based reimbursement. NATO markets are relevant for operational vision readiness, defense healthcare systems, and resilient medical supply chains across allied countries.

Key Country Insights Across Major Dry Eye Markets

The United States leads in prescription dry eye innovation, clinical trials, device adoption, and consumer awareness, while Canada shows steady demand through optometry-led care and access to preservative-free products. Mexico and Brazil are important Latin American markets where private ophthalmology, retail pharmacy channels, urbanization, and rising chronic disease prevalence support growth. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established eye care systems, aging demographics, and structured clinical pathways, while Russia presents demand shaped by local access, pricing, regulatory requirements, and supply conditions.

China and India offer major long-term volume potential because of population scale, digital lifestyles, pollution exposure, diabetes prevalence, and expanding specialist care. Japan and South Korea are sophisticated markets with high screen use, aging demographics, contact lens penetration, and strong ophthalmology adoption. Australia shows demand linked to aging, outdoor exposure, allergy burden, dry climate zones, and advanced optometry networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated portfolios that address both evaporative and aqueous-deficient dry eye, including preservative-free formulations, anti-inflammatory drugs, lipid-layer products, and device-enabled therapies for meibomian gland dysfunction. Evidence generation should include real-world outcomes, patient-reported improvement, objective sign changes, safety in chronic use, and comparative value versus standard care.

Organizations can accelerate growth by investing in clinician education, AI-enabled diagnostics, omnichannel patient engagement, and region-specific access strategies. Partnerships with ophthalmologists, optometrists, pharmacies, digital health platforms, and payers can improve diagnosis, adherence, and treatment continuity while strengthening credibility in a crowded dry eye market.

Research Methodology

This executive summary is built on validated secondary research and market intelligence synthesis, including clinical definitions from TFOS DEWS II, peer-reviewed dry eye epidemiology, regulatory frameworks, product approvals, treatment guidelines, healthcare infrastructure indicators, and regional access patterns. Insights were cross-checked to avoid unsupported claims and to reflect current clinical and commercial realities.

The methodology combines disease-burden assessment, segmentation by treatment modality and care pathway, regional demand mapping, technology trend analysis, and competitive landscape review. Qualitative interpretation was used only where supported by documented clinical practice, regulatory evidence, or observable market behavior, while avoiding market sizing, market share, and forecasting assumptions.

Conclusion

Dry Eye Syndrome is evolving from an often underrecognized discomfort condition into a clinically managed chronic ocular surface disease with strong demand for targeted, measurable, and long-term solutions. Growth is supported by aging, digitalization, environmental stressors, ocular procedures, chronic inflammatory conditions, and better diagnostic tools.

The strongest opportunities will favor organizations that combine science-backed therapies, objective diagnostics, AI-enabled personalization, clinician education, and locally relevant access models. As care becomes more phenotype-driven, the dry eye syndrome landscape is positioned for sustained innovation across pharmaceuticals, devices, diagnostics, and digital eye health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Dry Eye Syndrome Market, by Product Type

  • 7.1. Devices
  • 7.2. Eye Drops
  • 7.3. Eye Gels
  • 7.4. Eye Ointments
  • 7.5. Punctal Plugs

8. Dry Eye Syndrome Market, by Treatment Type

  • 8.1. Artificial Tears
  • 8.2. Medical Devices
  • 8.3. Nutraceuticals
  • 8.4. Prescription Drug Therapy
    • 8.4.1. Corticosteroids
    • 8.4.2. Cyclosporine
    • 8.4.3. Lifitegrast

9. Dry Eye Syndrome Market, by End User

  • 9.1. Clinics
  • 9.2. Home Care
  • 9.3. Hospitals

10. Dry Eye Syndrome Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Dry Eye Syndrome Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Dry Eye Syndrome Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Dry Eye Syndrome Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc.
  • 15.2. AFT Pharmaceuticals Ltd.
  • 15.3. Akorn Operating Company LLC
  • 15.4. Alcon Inc.
  • 15.5. Bausch + Lomb Corporation
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Kala Pharmaceuticals, Inc.
  • 15.8. Mitotech S.A.
  • 15.9. Novaliq GmbH
  • 15.10. Novartis AG
  • 15.11. OASIS Medical, Inc.
  • 15.12. Otsuka Pharmaceutical Co., Ltd.
  • 15.13. Rohto Pharmaceutical Co., Ltd.
  • 15.14. Santen Pharmaceutical Co., Ltd.
  • 15.15. Senju Pharmaceutical Co., Ltd.
  • 15.16. Similasan Corporation
  • 15.17. Sun Pharmaceutical Industries Ltd.
  • 15.18. Thea Pharmaceuticals Ltd.
  • 15.19. United Laboratories Co., Ltd.
  • 15.20. Ursapharm Arzneimittel GmbH
  • 15.21. Zhejiang Jianfeng Group Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRY EYE SYNDROME MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRY EYE SYNDROME MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRY EYE SYNDROME MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRY EYE SYNDROME MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRY EYE SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DRY EYE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EYE DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EYE DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EYE DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EYE GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EYE GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EYE GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EYE OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EYE OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EYE OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PUNCTAL PLUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PUNCTAL PLUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PUNCTAL PLUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRESCRIPTION DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRESCRIPTION DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRESCRIPTION DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CYCLOSPORINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CYCLOSPORINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CYCLOSPORINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIFITEGRAST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIFITEGRAST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIFITEGRAST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. GCC DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GCC DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. G7 DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. G7 DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NATO DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. NATO DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DRY EYE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CANADA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. CANADA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. CANADA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CANADA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. CANADA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. CANADA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. MEXICO DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. MEXICO DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. MEXICO DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. MEXICO DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. MEXICO DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MEXICO DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRAZIL DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. BRAZIL DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRAZIL DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. BRAZIL DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. BRAZIL DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. BRAZIL DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED KINGDOM DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GERMANY DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. GERMANY DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GERMANY DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GERMANY DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. GERMANY DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GERMANY DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. FRANCE DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. FRANCE DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. FRANCE DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. FRANCE DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. FRANCE DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. FRANCE DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. RUSSIA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. RUSSIA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. RUSSIA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. RUSSIA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. RUSSIA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. RUSSIA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ITALY DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. ITALY DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ITALY DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ITALY DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ITALY DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. ITALY DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. SPAIN DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. SPAIN DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. SPAIN DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. SPAIN DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. SPAIN DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. SPAIN DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. INDIA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. INDIA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. INDIA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. INDIA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. INDIA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. AUSTRALIA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, BY PRESCRIPTION DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. SOUTH KOREA DRY EYE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)